The inside story at Allergan is now firmly public, as the company’s plans to divest itself of certain product categories and acquire another firm were confirmed over the weekend.
What was rumored has become fact
This weekend Allergan publicly confirmed it will shed the firm's generic-drug business to Teva Pharmaceuticals for $40.5 billion and the company will purchase Naurex, a developer of antidepressant drugs, for $560 million.
On July 22 ValueWalk reported on a secret meeting that discussed a sales and marketing integration and aggressive acquisition strategy, citing unnamed sources. Then on July 24, Bloomberg reported Allergan was planning on separating its low priced generic business from its patented and higher-priced branded drug portfolio, again...
Login required to continue reading.
Setup a free account to get access to this article (no credit card required).
View Full Article
